Document is current
Any future updates will be listed below
-
Authors
Kerpel-Fronius, Anna https://orcid.org/0000-0002-8616-3366
Megyesfalvi, Zsolt
Markóczy, Zsolt
Solymosi, Diana
Csányi, Péter
Tisza, Judit
Kecskés, Anita
Baranyi, Beatrix
Csánky, Eszter
Dóka, Adrienn
Gálffy, Gabriella
Göcző, Katalin
Győry, Csilla
Horváth, Zsolt
Juhász, Tünde
Kállai, Árpád
Kincses, Zsigmond T.
Király, Zsolt
Király-Incze, Enikő
Kostyál, László
Kovács, Anita
Kovács, András
Kuczkó, Éva
Makra, Zsuzsanna
Maurovich Horvát, Pál
Merth, Gabriella
Moldoványi, István
Müller, Veronika
Pápai-Székely, Zsolt
Papp, Dávid
Polgár, Csaba
Rózsa, Péter
Sárosi, Veronika
Szalai, Zsuzsanna
Székely, András
Szuhács, Marianna
Tárnoki, Dávid
Tavaszi, Gábor
Turóczi-Kirizs, Róbert
Tóth, László
Urbán, László
Vaskó, Attila
Vigh, Éva
Dome, Balazs
Bogos, Krisztina
-
Funding
Funding for this research was provided by:
Emberi Eroforrások Minisztériuma (IV/2839-4/2021/EKF)
Hungarian National Research, Development and Innovation Office (2020-1.1.6-JÖVŐ, TKP2021-EGA-33, FK-143751)
Magyar Tudományos Akadémia (Bolyai Research Scholarship)
International Association for the Study of Lung Cancer (Young Investigator Grant (2022))
- License Information
-
More Information
Article History
Received: 5 June 2023
Revised: 28 August 2023
Accepted: 5 September 2023
First Online: 3 November 2023
Declarations
:
: The scientific guarantor of this publication is Krisztina Bogos, MD, PhD.
: Péter Rózsa is the CEO and Senior Health Economist of MediConcept Ltd. Gabriella Merth is an employee of MediConcept Ltd. The remaining authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: No complex statistical methods were necessary for this paper.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional review board approval was obtained. The national-level ethics committee (Hungarian Scientific and Research Ethics Committee of the Medical Research Council, approval number: ETT-TUKEB, 002524–005/2014/OTIG) and the local medical board of each participating site approved the study.
: No study subject overlap
: • prospective• diagnostic or prognostic study• multicenter study
